Caseware UK (AP4) 2025.0.111 2025.0.111 2026-02-28 2026-02-28 The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.2 No description of principal activity 2025-03-01 false 2 true true false 10643100 2025-03-01 2026-02-28 10643100 2024-03-01 2025-02-28 10643100 2026-02-28 10643100 2025-02-28 10643100 c:Director1 2025-03-01 2026-02-28 10643100 c:Director2 2025-03-01 2026-02-28 10643100 c:RegisteredOffice 2025-03-01 2026-02-28 10643100 d:MotorVehicles 2025-03-01 2026-02-28 10643100 d:MotorVehicles 2026-02-28 10643100 d:MotorVehicles 2025-02-28 10643100 d:MotorVehicles d:OwnedOrFreeholdAssets 2025-03-01 2026-02-28 10643100 d:ComputerEquipment 2025-03-01 2026-02-28 10643100 d:ComputerEquipment 2026-02-28 10643100 d:ComputerEquipment 2025-02-28 10643100 d:ComputerEquipment d:OwnedOrFreeholdAssets 2025-03-01 2026-02-28 10643100 d:OwnedOrFreeholdAssets 2025-03-01 2026-02-28 10643100 d:CurrentFinancialInstruments 2026-02-28 10643100 d:CurrentFinancialInstruments 2025-02-28 10643100 d:CurrentFinancialInstruments d:WithinOneYear 2026-02-28 10643100 d:CurrentFinancialInstruments d:WithinOneYear 2025-02-28 10643100 d:ShareCapital 2026-02-28 10643100 d:ShareCapital 2025-02-28 10643100 d:RetainedEarningsAccumulatedLosses 2026-02-28 10643100 d:RetainedEarningsAccumulatedLosses 2025-02-28 10643100 c:OrdinaryShareClass1 2025-03-01 2026-02-28 10643100 c:OrdinaryShareClass1 2026-02-28 10643100 c:OrdinaryShareClass1 2025-02-28 10643100 c:OrdinaryShareClass2 2025-03-01 2026-02-28 10643100 c:OrdinaryShareClass2 2026-02-28 10643100 c:OrdinaryShareClass2 2025-02-28 10643100 c:FRS102 2025-03-01 2026-02-28 10643100 c:AuditExempt-NoAccountantsReport 2025-03-01 2026-02-28 10643100 c:FullAccounts 2025-03-01 2026-02-28 10643100 c:PrivateLimitedCompanyLtd 2025-03-01 2026-02-28 10643100 2 2025-03-01 2026-02-28 10643100 e:PoundSterling 2025-03-01 2026-02-28 xbrli:shares iso4217:GBP xbrli:pure

Registered number: 10643100 ARDEN REGULATORY CLINICAL & MEDICAL CONSULTING LIMITED UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 28 FEBRUARY 2026
ARDEN REGULATORY CLINICAL & MEDICAL CONSULTING LIMITED CONTENTS
| Page
Company information | 1
Balance sheet | 2
Notes to the financial statements | 3 - 9
ARDEN REGULATORY CLINICAL & MEDICAL CONSULTING LIMITED COMPANY INFORMATION
Directors | Dr K P Mitchev
| Dr K J Ourumova
Registered number | 10643100
Registered office | 16 Great Queen Street
| Covent Garden
| London
| WC2B 5AH
Accountants | Blick Rothenberg Limited
| Chartered Accountants
| 16 Great Queen Street
| Covent Garden
| London
| WC2B 5AH
Page 1
|  | REGISTERED NUMBER:10643100
ARDEN REGULATORY CLINICAL & MEDICAL CONSULTING LIMITED BALANCE SHEET AS AT 28 FEBRUARY 2026
|  | 2026 |  | 2025
Note |  | £ |  | £
Fixed assets |  |  |  |  |
Tangible assets | 4 |  | 26,671 |  | 37,160
Current assets |  |  |  |  |
Debtors: amounts falling due within one year | 5 | 39,053 |  | 45,023 |
Cash at bank and in hand |  | 1,333,880 |  | 1,209,157 |
|  | 1,372,933 |  | 1,254,180 |
Creditors: amounts falling due within one year | 6 | (75,995) |  | (106,068) |
Net current assets |  |  | 1,296,938 |  | 1,148,112
Total assets less current liabilities |  |  | 1,323,609 |  | 1,185,272
Net assets |  |  | 1,323,609 |  | 1,185,272
Capital and reserves |  |  |  |  |
Called up share capital | 7 |  | 100 |  | 100
Profit and loss account |  |  | 1,323,509 |  | 1,185,172
Total equity |  |  | 1,323,609 |  | 1,185,272
The directors consider that the company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006. The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements. The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities. The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. The company has opted not to file the profit and loss account in accordance with provisions applicable to companies subject to the small companies' regime. The financial statements were approved and authorised for issue by the board and were signed on its behalf by:
Dr K J Ourumova
Director
Date: 18 August 2026
The notes on pages 3 to 9 form part of these financial statements. Page 2
ARDEN REGULATORY CLINICAL & MEDICAL CONSULTING LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 28 FEBRUARY 2026
1. | General information
Arden Regulatory Clinical & Medical Consulting Limited is a private company limited by shares incorporated in England and Wales. The address of its registered office is 16 Great Queen Street, Covent Garden, London, WC2B 5AH. The financial statements are presented in Sterling (£), which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £. 2.Accounting policies
| 2.1 | Basis of preparation of financial statements
The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view. The following principal accounting policies have been applied:
| 2.2 | Going concern
After making enquiries, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence and meet its liabilities as they fall due for the foreseeable future, being a period of at least twelve months from the date these financial statements were approved. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.
| 2.3 | Revenue
Revenue is recognised to the extent that it is probable that the economic benefits will flow to the company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised: Rendering of services Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied: ∙the amount of revenue can be measured reliably; ∙it is probable that the company will receive the consideration due under the contract; ∙the stage of completion of the contract at the end of the reporting period can be measured reliably; and ∙the costs incurred and the costs to complete the contract can be measured reliably. Page 3
ARDEN REGULATORY CLINICAL & MEDICAL CONSULTING LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 28 FEBRUARY 2026 2.Accounting policies (continued)
| 2.4 | Tangible fixed assets
Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management. At each reporting date the company assesses whether there is any indication of impairment. If such indication exists, the recoverable amount of the asset is determined which is the higher of its fair value less costs to sell and its value in use. An impairment loss is recognised where the carrying amount exceeds the recoverable amount. The company adds to the carrying amount of an item of fixed assets the cost of replacing part of such an item when that cost is incurred, if the replacement part is expected to provide incremental future benefits to the company. The carrying amount of the replaced part is derecognised. Repairs and maintenance are charged to profit or loss during the period in which they are incurred. Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method. The estimated useful lives range as follows:
|  |  |  | Motor vehicles | - | 4 | years
|  |  |  | Computer equipment | - | 3 | years
The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date. Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.
| 2.5 | Financial instruments
The company has elected to apply Sections 11 and 12 of FRS 102 in respect of financial instruments. Financial assets and financial liabilities are recognised when the company becomes party to the contractual provisions of the instrument. Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities. The company’s policies for its major classes of financial assets and financial liabilities are set out below. Financial assets Basic financial assets, including trade and other debtors and cash and bank balances are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest for a similar debt instrument. Financing transactions are those in which payment is deferred beyond normal business terms or is financed at a rate of interest that is not a market rate. Such assets are subsequently carried at amortised cost using the effective interest method, less any impairment. Page 4
ARDEN REGULATORY CLINICAL & MEDICAL CONSULTING LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 28 FEBRUARY 2026 2.Accounting policies (continued) Financial liabilities Basic financial liabilities, including trade and other creditors, are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Financing transactions are those in which payment is deferred beyond normal business terms or is financed at a rate of interest that is not a market rate. Debt instruments are subsequently carried at amortised cost, using the effective interest rate method. Impairment of financial assets Financial assets measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in the profit and loss account. For financial assets measured at cost less impairment, the impairment loss is measured as the difference between the asset's carrying amount and the best estimate of the amount the company would receive for the asset if it were to be sold at the reporting date. For financial assets measured at amortised cost, the impairment loss is measured as the difference between the asset's carrying amount and the present value of estimated cash flows discounted at the asset's original effective interest rate. If the financial asset has a variable interest rate, the discount rate for measuring any impairment loss is the current effective interest rate determined under the contract. If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been had the impairment not previously been recognised. The impairment reversal is recognised in profit or loss. Derecognition of financial assets and financial liabilities Financial assets are derecognised when (a) the contractual rights to the cash flows from the asset expire or are settled, or (b) substantially all the risks and rewards of the ownership of the asset are transferred to another party or (c) despite having retained some significant risks and rewards of ownership, control of the asset has been transferred to another party who has the practical ability to unilaterally sell the asset to an unrelated third party without imposing additional restrictions. Financial liabilities are derecognised when the liability is extinguished, that is when the contractual obligation is discharged, cancelled or expires. Offsetting of financial assets and financial liabilities Financial assets and liabilities are offset and the net amount reported in the balance sheet when there is an enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.
| 2.6 | Interest income
Interest income is recognised in profit or loss using the effective interest method. Page 5
ARDEN REGULATORY CLINICAL & MEDICAL CONSULTING LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 28 FEBRUARY 2026 2.Accounting policies (continued)
| 2.7 | Pensions
Defined contribution pension plan The company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the company pays fixed contributions into a separate entity. Once the contributions have been paid the company has no further payment obligations. The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Balance sheet. The assets of the plan are held separately from the company in independently administered funds.
| 2.8 | Cash
Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours.
| 2.9 | Share capital
Ordinary shares are classified as equity.
| 2.10 | Dividends
Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting. Page 6
ARDEN REGULATORY CLINICAL & MEDICAL CONSULTING LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 28 FEBRUARY 2026 2.Accounting policies (continued)
| 2.11 | Current and deferred taxation
The tax expense for the year comprises current and deferred tax. Tax is recognised in the profit and loss account, except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively. Current tax is the amount of income tax payable in respect of taxable profit for the year or prior years. The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the company operates and generates income. Deferred tax arises from timing differences that are differences between taxable profits and total comprehensive income as stated in the financial statements. These timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in the financial statements. Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the balance sheet date, except that: ∙The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and ∙Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met. Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the balance sheet date.
3. | Employees
| The average monthly number of employees, including directors, during the year was 2 (2025 - 2).
Page 7
ARDEN REGULATORY CLINICAL & MEDICAL CONSULTING LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 28 FEBRUARY 2026
4. | Tangible fixed assets
|  | Motor vehicles | Computer equipment | Total
|  | £ | £ | £
| Cost |  |  |
| At 1 March 2025 | 41,225 | 2,894 | 44,119
| At 28 February 2026 | 41,225 | 2,894 | 44,119
| Depreciation |  |  |
| At 1 March 2025 | 4,294 | 2,665 | 6,959
| Charge for the year | 10,306 | 183 | 10,489
| At 28 February 2026 | 14,600 | 2,848 | 17,448
| Net book value |  |  |
| At 28 February 2026 | 26,625 | 46 | 26,671
| At 28 February 2025 | 36,931 | 229 | 37,160
Page 8
ARDEN REGULATORY CLINICAL & MEDICAL CONSULTING LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 28 FEBRUARY 2026
5. | Debtors
|  |  |  |  | 2026 | 2025
|  |  |  |  | £ | £
| Trade debtors | 37,919 | 45,023
| Other debtors | 727 | -
| Prepayments | 407 | -
|  | 39,053 | 45,023
6. | Creditors: amounts falling due within one year
|  |  |  |  | 2026 | 2025
|  |  |  |  | £ | £
| Trade creditors | 168 | 146
| Corporation tax | 64,213 | 94,575
| Other taxation and social security | - | 3,367
| Other creditors | 3,953 | 1,730
| Accruals | 7,661 | 6,250
|  | 75,995 | 106,068
7. | Share capital
|  |  |  |  | 2026 | 2025
|  |  |  |  | £ | £
|  | Allotted, called up and fully paid |  |
|  | 50 (2025 - 50) Ordinary A shares of £1.00 each | 50 | 50
|  | 50 (2025 - 50) Ordinary B shares of £1.00 each | 50 | 50
|  |  | 100 | 100
8. | Related party transactions
| Included within other creditors is £3,953 (2025 - £1,730) owed to the directors of the company. This amount is interest-free and unsecured and repayable on demand.
Page 9